Plenary Session

In this REUP episode, we replay a section of our interview with Dr. Adam Obley of OHSU: a primer on cancer screening. This audio was first aired on episode 2.03. Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreo...

In this REUP episode, we replay a section of our interview with Dr. Michael Hayes of Kaiser Permanente. This audio was first aired on episode 2.01. The interview is on the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme. TTF: doi.org/10.1016/j.jcpo.2019.100189 Back us on Patreon! www.patreon.com/plenarysession

This week we launch a new segment on Plenary Session: Question of the Week! We invite Dr. Sven Olson on to ask a sample hematology/oncology boards question and we invite Audrey Tran on to ask a question from a medical student. Before that, we talk about the legacy of Dr. Charles Moertel and how modern oncologists, in contrast, will be remembered. We end the episode with an interview with Dr. Adam...

This BONUS episode is a recording of a lecture that Dr. Stacie Dusetzina of Vanderbilt University gave for grand rounds at OHSU on June 19, 2019. The lecture is on the cost of prescription drugs and out-of-pocket spending. Back us on Patreon! www.patreon.com/plenarysession

Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationshi...

We begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of c...

This week we begin the episode by discussing MONALEESA-7 and why ribociclib has been shown to increase overall survival while palbociclib has not. We finish the episode with an in-depth interview with Dr. Stacie Dusetzina of Vanderbilt University on her work in pharmacoeconomics, specifically we discuss her work on the market value of cancer drugs. MONALEESA-7: doi.org/10.1056/NEJMoa1903765 Free d...

This week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clin...

In this BONUS episode we give advice on how to use Twitter effectively: how to focus your content, how to build your Twitter following, and how to conceptualize of the platform as an information network. Back us on Patreon! www.patreon.com/plenarysession

This week we discuss the recent paper "Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?" with its author, Dr. Joaquín Chapa of OHSU. We then revisit the POLO trial with Dr. Emerson Chen of OHSU, who disagrees with last episode's analysis. Effectiveness of Screening: doi.org/10.1016/j.mayocp.2019.02.016 POLO: doi.org/10.1056/NEJMoa1903387...

This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", whi...

We begin this episode by responding to listener feedback from episode 1.61's discussion of clinic appointment time and rates of cancer screening. We also tackle listeners' outcry over our take-down of BILCAP (spoiler alert: BILCAP is still a null trial) and how outcry like this highlights the need to train clinicians to think probabilistically. From there, we move on to discussing the recent paper...

This week we cover three papers -- "Postpublication Metrics of Randomized Clinical Trials With and Without Null Findings" by Murray et al. in JAMA, "Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening" by Hsiang et al. in JAMA Network Open, and "Exceptional responders with invasive mucinous adenocarcinomas: a...

We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs. Imputability of Adverse Events: doi.org/10.1056/NEJM...

In this BONUS episode, we interview Palmer Greene, a fourth-year medical student at the University of Chicago Pritzker School of Medicine, on his recent paper: "Should Evidence Come with an Expiration Date?", published in the Journal of General Internal Medicine. Expiration Date?: doi.org/10.1007/s11606-019-05032-4 Back us on Patreon! www.patreon.com/plenarysession

This week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University. WINTHER: doi.org/10.1038/s41591-019-0424-4 T...

In this BONUS episode, we interview Dr. Talal Hilal of the Mayo Clinic on his paper that was published today in JAMA Oncology, titled "Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration". Control Arm Quality: doi.org/10.1001/jamaoncol.2019.0167 Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a Grand Rounds lecture that Dr. Christopher Booth of Queen's University in Kingston, Canada gave this morning (May 1, 2019) at OHSU. The title is "Achieving the Achievable: Real World Data and the Search for Meaningful Cancer Care". Back us on Patreon! www.patreon.com/plenarysession

This week we sit down with Dr. Cliff Hudis, the CEO of the American Society of Clinical Oncology, to discuss the role of a professional society, the evolution of oncology, building a career, and more. Back us on Patreon! www.patreon.com/plenarysession

In this week's episode, we break down two recently published papers. The first is "Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database" by Singal et al., published in JAMA. The second is "Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligome...

We begin this episode with a discussion of two recent clinical trials in lymphoma: CALGB 50303 and REMoDL-B, respectively published in the Journal of Clinical Oncology and The Lancet Oncology. We include a primer on the history of lymphoma and the development of R-CHOP. We follow that with an in-depth interview with Dr. Ameet Sarpatwari of the Harvard Medical School on Risk Evaluation and Mitigati...

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for pa...

In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months. Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351 Back us on Patreon! www.patr...

This week we tackle the recent paper published in the Journal of Clinical Oncology titled "Comparison of Population-Based Observational Studies With Randomized Trials in Oncology" as well as a couple papers lamenting physicians' use of Twitter and the open-access model for journal publishing. We end the episode with an in-depth interview with Dr. Kathryn Schabel of OHSU on orthopedic surgery and h...

We begin this episode by answering questions from a med student who is a Plenary Session fan. We transition from there to a discussion of the recent news stories on the FAA's handling of the Boeing 737 Max controversy and how this reflects on other USA regulatory agencies like the FDA. After a critique of the recent paper "Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression...